Raltegravir pharmacokinetics during pregnancy

Raltegravir pharmacokinetics during pregnancy

Copyright © 2014 by Lippincott Williams & Wilkins. Objective: We evaluated the pharmacokinetics (PK) of raltegravir in HIV-infected women during pregnancy and postpartum. Methods: International Maternal Pediatric Adolescent AIDS Clinical Trials 1026s is an ongoing prospective study of antiretr...

Full description

Saved in:

Bibliographic Details
Main Authors:	D. Heather Watts, Alice Stek, Brookie M. Best, Jiajia Wang, Edmund V. Capparelli, Tim R. Cressey, Francesca Aweeka, Patty Lizak, Regis Kreitchmann, Sandra K. Burchett, David E. Shapiro, Elizabeth Hawkins, Elizabeth Smith, Mark Mirochnick
Format:	Journal
Published:	2018
Online Access:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84922481121&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/45818
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Chiang Mai University

Similar Items

Raltegravir pharmacokinetics during pregnancy
by: D. Heather Watts, et al.
Published: (2018)

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy
by: Regis Kreitchmann, et al.
Published: (2018)

Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy
by: Regis Kreitchmann, et al.
Published: (2018)

Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women
by: Alice Stek, et al.
Published: (2018)

Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women
by: Alice Stek, et al.
Published: (2018)

Efavirenz pharmacokinetics during pregnancy and infant washout
by: Regis Kreitchmann, et al.
Published: (2019)

Reduced indinavir exposure during pregnancy
by: Tim R. Cressey, et al.
Published: (2018)

Reduced indinavir exposure during pregnancy
by: Tim R. Cressey, et al.
Published: (2018)

Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling
by: Xiaomei I. Liu, et al.
Published: (2020)

Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
by: Tim R. Cressey, et al.
Published: (2018)

Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy
by: Ahizechukwu C. Eke, et al.
Published: (2020)

Simultaneous determination of raltegravir and raltegravir glucuronide in human plasma by liquid chromatography-tandem mass spectrometric method
by: Wang, L.-Z., et al.
Published: (2014)

Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy
by: Tim R. Cressey, et al.
Published: (2018)

Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy
by: Tim R. Cressey, et al.
Published: (2018)

Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial
by: Esaú C. João, et al.
Published: (2020)

Pharmacokinetic modeling of plasma and intracellular concentrations of raltegravir in healthy volunteers
by: Wang, L., et al.
Published: (2014)

Acceptability and Feasibility of Using Raltegravir Oral Granules for the Treatment of Neonates in a Low-resource Setting
by: Moherndran Archary, et al.
Published: (2020)

Phenotyping of UGT1A1 Activity Using Raltegravir Predicts Pharmacokinetics and Toxicity of Irinotecan in FOLFIRI
by: Lee L.S.-U., et al.
Published: (2018)

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
by: Pedro Cahn, et al.
Published: (2018)

Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations
by: Diana F. Clarke, et al.
Published: (2018)

Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations
by: Diana F. Clarke, et al.
Published: (2018)

Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
by: Cressey T., et al.
Published: (2017)

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling
by: Stein Schalkwijk, et al.
Published: (2019)

Developmental pharmacokinetic changes of lamivudine in infants and children
by: Adriana H. Tremoulet, et al.
Published: (2018)

Innovative Approaches for Pharmacology Studies in Pregnant and Lactating Women: A Viewpoint and Lessons from HIV
by: Ahizechukwu C. Eke, et al.
Published: (2020)

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
by: Stein Schalkwijk, et al.
Published: (2018)

A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400 mg in Pregnant Women
by: Stein Schalkwijk, et al.
Published: (2018)

Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
by: Wasana Prasitsuebsai, et al.
Published: (2018)

Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation
by: Wasana Prasitsuebsai, et al.
Published: (2018)

Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience
by: Mina Nikanjam, et al.
Published: (2018)

A phase II/III trial of lopinavir/ritonavir dosed according to the WHO pediatric weight band dosing guidelines
by: Jorge A. Pinto, et al.
Published: (2018)

Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine
by: Kulkanya Chokephaibulkit, et al.
Published: (2018)

Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine
by: Kulkanya Chokephaibulkit, et al.
Published: (2018)

Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
by: Tim R. Cressey, et al.
Published: (2018)

Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women
by: Tim R. Cressey, et al.
Published: (2018)

Raltegravir 1200 mg once daily vs 400 mg twice daily, with emtricitabine and tenofovir disoproxil fumarate, for previously untreated HIV-1 infection: Week 96 results from ONCEMRK, a randomized, double-blind, noninferiority trial
by: Pedro Cahn, et al.
Published: (2019)

Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women
by: Anna H. Tran, et al.
Published: (2018)

Cookie, amah, and master: a look into divergent experiences and colonial attitudes
by: Poey, Elizabeth Francesca Rui Ying
Published: (2024)

Developmental pharmacokinetic changes of lamivudine in infants and children
by: Tremoulet A.H., et al.
Published: (2014)

Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women
by: Soranun Chantarangsu, et al.
Published: (2018)